The article presents information on multiple myeloma, a cancer of the plasma cells in the bone marrow. It describes how myeloma cells affect bones, kidneys, blood and other organs. It outlines the signs and symptoms of multiple myeloma, including bone pain...
There is often a substantial delay between the onset of symptoms attributable to the disease and the diagnosis. For example, among the last 1000 patients entered into Medical Research Council's multiple myeloma trials this delay was over three months in 350 patients and over six months in 150....
Damage to the bones from multiple myeloma may release too much calcium into the blood. This causes hypercalcemia, a condition that may cause symptoms including: Nausea, vomiting or loss of appetite. Constipation and other digestive issues.
524Scopus citations Abstract There appear to be 2 pathways involved in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) tumors. Nearly half of these tumors are nonhyperdiploid and mostly have imm...
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. Image credit: freshidea | stock.adobe.com During a presentation at the National Comprehensive Cancer Network Annual 2024 Conference in Orlando, ...
by the presence ofnormocytic normochromic anemiaandmild renal failureorhypergammaglobulinemia. Because of the catabolic effects of myeloma-associated cytokines, older patients may present with normocytic anemia and a drop in serum cholesterol, even before other signs or symptoms of the disea...
If you know the early signs and symptoms of multiple myeloma, then you can be able to detect it when it is still in its early stages. This will help you to get medical intervention in time. Multiple Myeloma’s Effect on Your Body ...
The current definition of plasma cell leukemia (PCL)— ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109/L—may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who ha...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for anot